Cereplast, Viral Genetics add new members to corporate teams

By Erin Voegele | February 29, 2012

Two biorefining companies have announced new additions to their teams this week. California-based bioplastic producer Cereplast Inc. has announced a new addition to its Board of Directors, while Viral Genetics Inc. has added a new corporate development advisor.

Cereplast has appointed Paul Pelosi Jr. to its Board of Directors. According to information released by the company, Pelosi has 16 years of experience advising emerging and Fortune 500 companies in the areas of finance, infrastructure, sustainability and public policy. He was appointed by San Francisco Mayor Willie Brown to the city’s Commission of the Environment in 2003, and served as its president. Pelosi most recently served as director of WR Hambrecht. He currently serves as an advisor to governmental and private companies, including NASA Ames Research Center and AirPatrol Corp. He has also worked for InfoUSA, Bank of America Securities and JPMorgan Chase.

“Mr. Pelosi is a key addition to our Board,” said Cereplast Chairman and CEO Frederic Scheer. “We are confident he will assist Cereplast's efforts to bring our proprietary biobased, sustainable bioplastics to the worldwide marketplace. In addition to having an extensive network and a strong financial background, Mr. Pelosi has been influential in assisting in the creation of several important environmental policies and programs in the United States. He was influential in San Francisco becoming the first municipality to implement a ban on plastic bags. We look forward to working with Mr. Pelosi and benefitting from his knowledge and expertise in environmental matters.”

Viral Genetics, which is the majority owner of VG Energy, has added Nathan Tinker as its corporate development advisor. According to Viral Genetics, Tinker will focus on marketing the company’s drug and biofuel technologies to potential strategic partners.

Tinker currently serves as executive director of the New York Biotechnology Association, which is a nonprofit trade association that promotes the development and growth of bioscience-related industries and institutions. Before joining NYBA, Tinker led the Sabin Vaccine Institute’s Cancer Vaccine Consortium and was a co-founder of NanoBusiness Alliance, which is now known as the NanoBusiness Commercialization Association.

“Viral Genetics and VG Energy provide the strategic partnering marketplace with some of the most interesting science and technology opportunities that I have encountered in an emerging company,” Tinker said. “The two core technologies are exactly the types of assets that potential industry partners are seeking: they are platform technologies offering a number of potential product development opportunities in major markets and not just 'one-trick ponies;' the intellectual property securing them is well-established through a series of patents and patent applications; and they hold the promise of offering significant advances to their respective end-markets—novel mechanisms of disease treatment and advanced biofuels.